Filing Details
- Accession Number:
- 0000950170-24-098803
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-19 20:13:31
- Reporting Period:
- 2024-08-19
- Accepted Time:
- 2024-08-19 20:13:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1607678 | Viking Therapeutics Inc. | VKTX | Pharmaceutical Preparations (2834) | 461073877 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1614578 | Brian Lian | C/O Viking Therapeutics, Inc. 9920 Pacific Heights Blvd, Suite 350 San Diego CA 92121 | President & Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.00001 Per Share | Acquisiton | 2024-08-19 | 112,870 | $7.77 | 2,467,797 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-08-19 | 70,132 | $65.33 | 2,397,665 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-08-19 | 31,442 | $66.37 | 2,366,223 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.00001 Per Share | Disposition | 2024-08-19 | 11,296 | $67.12 | 2,354,927 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-08-19 | 112,870 | $0.00 | 112,870 | $7.77 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 232,130 | 2021-01-03 | 2030-01-03 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.90 to $65.8919, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.93 to $66.9091, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.9302 to $67.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 25% of the shares subject to the option vested on each anniversary of the grant date.
Billionaire Hedge Funds
